Literature DB >> 21978690

A novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease.

Q Shi1, Z Y Gao, F Xie, L F Wang, Y P Gu, T J Yang, L Huang, Q H Qian, Yu Hua Qiu.   

Abstract

Blockade of the interactions between CD28/CTLA-4 and their ligands, CD80 (B7, B7.1)/CD86 (B70, B7.2), is an attractive means to induce antigen-specific peripheral tolerance in autoimmune disease and organ transplantation. In this study, we generated and characterized a monoclonal antibody (Clone 4E5) against human CD80. 4E5 could recognize both human and mouse CD80 and suppress mixed lymphocyte reaction in vitro. To investigate their potency for clinical use, we further administrated 4E5 to a mouse lupus-like disease model (C57BL/J6) induced by Pristane. 4E5 could inhibit the immune response and attenuate the severity of lupus-like disease. The data showed 4E5 function and suggested that blockade of CD80/CD28 co-stimulatory signal pathway with 4E5 is a promising strategy to decelerate the progression of lupus-like disease and other autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21978690     DOI: 10.1177/039463201102400304

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  9 in total

Review 1.  An update on lupus animal models.

Authors:  Wei Li; Anton A Titov; Laurence Morel
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

2.  Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells.

Authors:  Seth D Reighard; Stacey A Cranert; Kelly M Rangel; Ayad Ali; Ivayla E Gyurova; Arthur T de la Cruz-Lynch; Jasmine A Tuazon; Marat V Khodoun; Leah C Kottyan; David F Smith; Hermine I Brunner; Stephen N Waggoner
Journal:  Cell Rep Med       Date:  2020-03-25

Review 3.  Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus.

Authors:  Nien Yee Kow; Anselm Mak
Journal:  Clin Dev Immunol       Date:  2013-07-29

4.  Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway.

Authors:  Li Huang; Yong Kong; Jing Wang; Jie Sun; Qin Shi; Yu-Hua Qiu
Journal:  Mol Med Rep       Date:  2015-06-18       Impact factor: 2.952

Review 5.  Immune checkpoint receptors in regulating immune reactivity in rheumatic disease.

Authors:  Sabrina Ceeraz; Elizabeth C Nowak; Christopher M Burns; Randolph J Noelle
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

Review 6.  CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.

Authors:  Yoong Mond Teh; Soo Kun Lim; Norhana Jusoh; Kahar Osman; Siti Aisyah Mualif
Journal:  Biomed Res Int       Date:  2021-01-06       Impact factor: 3.411

7.  Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.

Authors:  Cindy Orvain; Anne Cauvet; Alexis Prudent; Christophe Guignabert; Raphaël Thuillet; Mina Ottaviani; Ly Tu; Fanny Duhalde; Carole Nicco; Frédéric Batteux; Jérôme Avouac; NingXin Wang; Michelle A Seaberg; Stacey R Dillon; Yannick Allanore
Journal:  Arthritis Res Ther       Date:  2022-01-05       Impact factor: 5.156

8.  Comparative effects of n-3, n-6 and n-9 unsaturated fatty acid-rich diet consumption on lupus nephritis, autoantibody production and CD4+ T cell-related gene responses in the autoimmune NZBWF1 mouse.

Authors:  James J Pestka; Laura L Vines; Melissa A Bates; Kaiyu He; Ingeborg Langohr
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

9.  A novel monoclonal antibody against human B7-1 protects against chronic graft-vs.-host disease in a murine lupus nephritis model.

Authors:  Lijun Shen; Ying Zhu; Lianhua Han; Yuyu Wang; Tianming Yan; Yong Kong; Shitao Zou; Yuhua Qiu; Yan Xu
Journal:  Exp Ther Med       Date:  2020-08-25       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.